



Treatment Intensification in Localized Prostate Cancer: What Route with What Car?

Guest Editors:

Dr. Paul Sargos

Department of Radiation
Oncology, Institut Bergonie,
Bordeaux, France

Dr. Igor Latorzeff

Department of Radiotherapy,
Clinique Pasteur, Toulouse,
France

Dr. Vedang Murthy

Department of Radiation
Oncology, ACTREC, Tata
Memorial Centre, Parel, Mumbai,
Maharashtra, India

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

For patients with prostate cancer (PCa) treated with radiotherapy, support for intensification with abiraterone and androgen deprivation therapy (ADT) is the new standard of care based on the STAMPEDE trial. Nevertheless, appropriately intensified radiotherapy could be complementary or even an alternative to systemic intensification for selected patients. Evidence from contemporary randomized trials in highrisk prostate cancer shows that the intensification of prostate radiotherapy—via brachytherapy (ASCENDE-RT), intraprostatic boost (FLAME), or elective pelvic irradiation (POPRT)—results in 5 yr metastasis-free survival (MFS) of 90–95% with ADT alone. Results from ongoing trials evaluating the same strategy in the post-operative setting are awaited. The aim of this Topic Issue is to review evidence regarding treatment intensification in localized PCa, describing rationale, oncological outcomes, tolerance and perspectives.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)